Trial Profile

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilvegostomig (Primary) ; Volrustomig (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms GEMINI-Gastric
Sponsors AstraZeneca; AstraZeneca AB

18 Mar 2026 Planned number of patients changed from 240 to 163.
18 Mar 2026 Planned End Date changed from 28 Sep 2027 to 31 May 2029.
18 Mar 2026 Planned primary completion date changed from 3 Jul 2026 to 30 Nov 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com